drugset / Trial / NCT03316898
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a study to evaluate the brain metabolic response using Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), safety, tolerability and pharmacokinetics of AGN-242071 in patients with mild to moderate Alzheimer's Disease on a stable dose of 10 mg donepezil with or without memantine standard of care.
Timeline
- Start
- 2018-09-30
- Primary completion
- 2018-11-04
- Completion
- 2018-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGN-242071 | Unknown | 5 mg | — |
| Subject | AGN-242071 | Unknown | 15 mg | — |
| Subject | AGN-242071 | Unknown | 25 mg | — |
| Background | Donepezil | Small molecule | 10 mg | — |
| Background | Memantine | Unknown | — | — |